Learn about vesicular monoamine transporter 2 (VMAT2) inhibitors, a medication used to manage chorea, or uncontrolled movements, in Huntington’s disease.

"The KINECT-HD study demonstrated INGREZZA's ability to significantly reduce chorea, one of the most visible and disruptive symptoms of Huntington's disease, which often occurs alongside cognitive ...

SAN DIEGO, March 17, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from the KINECT®-HD study showcasing significant improvements in chorea across body regions ...

Prilenia’s Pridopidine for Huntington ... chorea and behavioral complications,” said Dr. Ralf Reilmann, Board Certified Neurologist and Founding Director of the George-Huntington ...

--Neurocrine Biosciences, Inc. presented data from the KINECT ®- HD study showcasing significant improvements in chorea across body regions with once-daily INGREZZA ® capsules in adults with ...

SAN DIEGO, March 17, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from the KINECT ®-HD study showcasing significant improvements in chorea across body regions ...